Brand: TumorDefence
Formulated For: Adjuvant treatment for cancer patients to enhance survival and quality of life
Health Canada Regulatory Status: Currently assembling data so as to apply for RCT permission.

Additional Information:
Requires a multi-center, double-blind, placebo-control, fully randomize clinical. Estimates received to date indicate a cost of $2.5 million Canadian dollars to conduct such a study, which means government or private section funding will need to be undertaken to complete the RCT.